

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Life360, Inc.</b>
<b>ARBN: 629 412 942</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Christopher (Chris) Hulls
<b>Date of last notice</b>	15 March 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct Interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	29 May 2024 (PDT) (being 30 May 2024 AEST)
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"><li>3,513,874 CHESS Depositary Interests (CDIs)</li><li>951,032 Shares of Common Stock (<b>Shares</b>)(equivalent to 2,853,096 CDIs)</li><li>2,090,348 Options over Shares (<b>Options</b>)</li><li>45,669 Restricted Stock Units (<b>RSUs</b>)</li><li>29,960 Shares held by ICCA Labs, LLC<sup>1</sup> )(equivalent to 89,880 CDIs)</li></ul>

<sup>1</sup> Chris Hulls is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of Shares attributable to Chris Hulls by reason of his membership interest in ICCA Labs, LLC is 29,960. Since the lodgement of the most recent Appendix 3Y on 15 March 2024, a transmutation event took place whereby 89,880 CDIs converted to 29,960 shares, with Mr Hull's overall membership interest in Life360 through ICCA Labs, LLC remaining unchanged.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class</b>	RSUs and Performance Restricted Stock Units (PRSUs)
<b>Number acquired</b>	40,885 RSUs 61,328 PRSUs
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	RSUs and PRSUs are granted for no consideration. RSUs granted have a value of US\$1,200,000. PRSUs granted have a value of US\$3,600,000.
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 3,513,874 CDIs</li> <li>• 951,032 Shares (equivalent to 2,853,096 CDIs)</li> <li>• 2,090,348 Options</li> <li>• 86,554 RSUs</li> <li>• 61,328 PRSUs</li> <li>• 29,960 Shares held by ICCA Labs, LLC )(equivalent to 89,880 CDIs)</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Granting of RSUs and PRSUs approved at the 2024 AGM and issued under the Restated and Amended 2011 Stock Plan.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.